drugset / Trial / NCT04519164
Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will evaluate whether the mineralocorticoid receptor antagonist eplerenone, when compared to chlorthalidone plus potassium chloride, can improve cardiac MRI-derived myocardial perfusion reserve and fibrosis, independent of blood pressure, and proportionately to the severity of autonomous aldosterone production.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2025-09-17
- Completion
- 2025-09-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Chlorthalidone | Other / unclassified | 6.25 mg | — |
| Comparator | Chlorthalidone | Other / unclassified | 25 mg | — |
| Subject | Eplerenone | Unknown | 25 mg | — |
| Subject | Eplerenone | Unknown | 100 mg | — |
| Comparator | Potassium Chloride | Small molecule | 20 meq | — |